So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.

CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

Funding supports safety studies, manufacturing and clinical planning needed before applying to test the treatment in patients ...

Cell and gene therapy are revolutionary approaches to treating diseases at the molecular level. They involve the manipulation ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

Researchers have unlocked a way to grow the immune system’s “conductors” from stem cells, bringing ready-made cancer-fighting therapies a big step closer. For the first time, scientists at the Univers ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Ascidian Therapeutics and Forge Biologics have partnered to advance the development and manufacturing of ACDN-01.

This article explores the US and EU compliance requirements to ensure patient safety for GMP ancillary materials in cell and ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential ...